BPG is committed to discovery and dissemination of knowledge
Articles in Press
4/20/2026 6:51:23 AM | Browse: 4 | Download: 0
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 120019
Country Czech Republic
Category Oncology
Manuscript Type Evidence Review
Article Title Bridging the intraductal papillary mucinous neoplasm risk stratification gap: A critical review of current and emerging biomarkers
Manuscript Source Unsolicited Manuscript
All Author List Peter Mačinga, Jiří Zahradník, Tomáš Hucl and Radoslav Janoštiak
Funding Agency and Grant Number
Funding Agency Grant Number
Czech Health Research Council NU23J-06-00043
Charles University PRIMUS Program PRIMUS/22/MED/007
European Union-Next Generation EU, Programme EXCELES LX22NPO5102
Corresponding Author Radoslav Janoštiak, Associate Professor, PhD, Professor, BIOCEV, First Faculty of Medicine, Charles University, Průmyslová 595, Vestec 25250, Czech Republic. radoslav.janostiak@lf1.cuni.cz
Key Words Pancreatic cancer; Intraductal papillary mucinous neoplasms; Biomarker; Risk stratification; Cyst fluid; Liquid biopsy
Core Tip Current guidelines for intraductal papillary mucinous neoplasm management inadequately distinguish indolent lesions from high grade dysplasia, resulting in both overtreatment and missed cancer. This evidence review critically examines established and emerging circulating and cyst fluid biomarkers, including molecular, inflammatory, and glycoprotein markers. We emphasize diagnostic performance, methodological limitations, and translational barriers. We highlight the impact of pooled histological endpoints, small surgical cohorts, assay heterogeneity, and lack of multicenter validation on the accuracy of the current studies. Finally, we outline the requirements needed to clinically integrate these biomarkers into intraductal papillary mucinous neoplasm risk stratification.
Citation Mačinga P, Zahradník J, Hucl T, Janoštiak R. Bridging the intraductal papillary mucinous neoplasm risk stratification gap: A critical review of current and emerging biomarkers. World J Gastrointest Oncol 2026; In press
Received
2026-02-13 02:50
Peer-Review Started
2026-02-13 02:54
First Decision by Editorial Office Director
2026-03-04 09:11
Return for Revision
2026-03-06 09:56
Revised
2026-03-31 18:51
Publication Fee Transferred
Second Decision by Editor
2026-04-20 02:56
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2026-04-20 06:51
Articles in Press
2026-04-20 06:51
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright ©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com